DUPIXENT IS THE FIRST AND ONLY FDA-APPROVED DUAL INHIBITOR of IL-4 and IL-13 Signaling, TWO OF THE Key Drivers of Type 2 Inflammation1,a
select a condition
APPROVED INDICATIONS WORLDWIDE2,b
aThe mechanism of dupilumab action has not been definitively established.
bThis worldwide number is largely comprised from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the rest of the world comprising ≈10% of this number. This number is comprised of the following US approved indications: AD, asthma, CRSwNP, PN, and EoE. Data through August 2024.
dosing
ENROLL YOUR PATIENTS
IN DUPIXENT MyWay®
DUPIXENT MyWay is a patient support program that can
help your patients access DUPIXENT and find support
throughout their treatment journey. Download and fill out
the enrollment form with your patients.
Moderate-to-Severe Asthma
Moderate-to-Severe Atopic Dermatitis
Chronic Obstructive Pulmonary Disease
Chronic Rhinosinusitis with Nasal Polyps
Eosinophilic Esophagitis
Prurigo Nodularis
QUESTIONS ABOUT DUPIXENT MyWay?
Call 1-844-DUPIXEN(T)
(1-844-387-4936), option 1
Monday-Friday, 8 am to 9 pm ET
Or click below to learn more:
LEARN ABOUT DUPIXENT MyWayDosing & Administration
DUPIXENT offers 2 administration options: the pre-filled pen (indicated ages 2+ years) and the pre-filled syringe (indicated ages 6+ months). Both options are available in 200 mg and 300 mg doses and can be self-administered at home (after proper training by a healthcare provider) or administered in your office.
Contact a Representative
Speak to a live representative who can answer questions about clinical data, dosing, and more.